A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

ClinicalTrials.gov ID: NCT04422912

Public ClinicalTrials.gov record NCT04422912. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 2:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris

Study identification

NCT ID: NCT04422912
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Cabaletta Bio; Industry
Enrollment: 40 participants

Conditions and interventions

Conditions

Pemphigus Vulgaris

Interventions

CABA-201 Biological
DSG3-CAART Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 28, 2020
Primary completion: Dec 31, 2028
Completion: Dec 31, 2028
Last update posted: May 14, 2026

2020 – 2029

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 12

Facility	City	State	ZIP	Site status
Stanford University, Dept. of Dermatology	Redwood City	California	94063	Recruiting
UC Davis, Dept. of Dermatology	Sacramento	California	95816	Recruiting
Yale University	New Haven	Connecticut	06520	Recruiting
Northwestern University	Chicago	Illinois	60611	Recruiting
University of Iowa	Iowa City	Iowa	52242	Recruiting
Brigham and Women's Hospital	Boston	Massachusetts	02115	Recruiting
Mount Sinai - Icahn School of Medicine	New York	New York	10029	Withdrawn
Columbia University	New York	New York	10032	Recruiting
University of North Carolina, Department of Dermatology	Chapel Hill	North Carolina	27516	Withdrawn
University of Pennsylvania	Philadelphia	Pennsylvania	19104	Recruiting
UT Southwestern Medical Center, Dept. of Dermatology	Dallas	Texas	75235	Recruiting
MD Anderson Texas Medical Center	Houston	Texas	77030	Recruiting
University of Washington	Seattle	Washington	98109	Completed

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04422912, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 14, 2026 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04422912 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →